Tracon Pharmaceuticals, Inc.
TCON evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Lead Asset:
- envafolimab (Phase 2)
What it means
What to watch
Prepared research question
What matters most for TCON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
envafolimab (Phase 2)
Next Catalyst
—
Tracking 3 pipeline candidates · 1 clinical trial for Tracon Pharmaceuticals, Inc..
Run Tracon Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tracon Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Tracon Pharmaceuticals, Inc.'s lead drug candidate?
Tracon Pharmaceuticals, Inc.'s most advanced tracked candidate is envafolimab (Phase 2) for sarcoma (specifically undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS)).
Who is the CEO of Tracon Pharmaceuticals, Inc.?
Craig Jalbert Craig is the chief executive officer of Tracon Pharmaceuticals, Inc. (TCON).
What therapeutic areas does Tracon Pharmaceuticals, Inc. focus on?
Tracon Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.